Ginkgo Bioworks Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Cell Engineering revenue (1) | $75,089 | $37,176 | $139,183 | $116,555 |
| Biosecurity revenue: | ||||
| Product | — | 6,495 | — | 28,949 |
| Service | 13,957 | 11,759 | 44,013 | 71,196 |
| Total revenue | 89,046 | 55,430 | 183,196 | 216,700 |
| Costs and operating expenses: | ||||
| Cost of Biosecurity product revenue | — | 906 | — | 7,481 |
| Cost of Biosecurity service revenue | 9,987 | 6,017 | 30,996 | 39,913 |
| Cost of other revenue | 2,016 | — | 3,930 | — |
| Research and development | 77,006 | 156,662 | 347,684 | 463,583 |
| General and administrative | 52,292 | 82,028 | 188,864 | 295,802 |
| Impairment of lease assets | — | 96,210 | — | 96,210 |
| Goodwill impairment | — | — | 47,858 | — |
| Restructuring charges | 2,949 | — | 20,015 | — |
| Total operating expenses | 144,250 | 341,823 | 639,347 | 902,989 |
| Loss from operations | (55,204) | (286,393) | (456,151) | (686,289) |
| Other income (expense): | ||||
| Interest income, net | 9,251 | 15,020 | 31,275 | 43,914 |
| Loss on equity method investments | — | — | — | (1,516) |
| Loss on investments | (6,912) | (36,324) | (16,282) | (44,815) |
| Loss on deconsolidation of subsidiary | (7,013) | — | (7,013) | — |
| Change in fair value of warrant liabilities | 1,528 | 1,891 | 5,701 | (1,387) |
| Other income, net | 1,572 | 2,893 | 2,821 | 9,045 |
| Total other income (expense) | (1,574) | (16,520) | 16,502 | 5,241 |
| Loss before income taxes | (56,778) | (302,913) | (439,649) | (681,048) |
| Income tax expense (benefit) | (375) | (22) | (154) | 127 |
| Net loss | $(56,403) | $(302,891) | $(439,495) | $(681,175) |
| Net loss per share, basic and diluted | $(1.08) | $(6.21) | $(8.58) | $(14.09) |
| Weighted average common shares outstanding: | ||||
| Basic | 52,240 | 48,770 | 51,244 | 48,330 |
| Diluted | 52,246 | 48,770 | 51,250 | 48,330 |
| Comprehensive loss: | ||||
| Net loss | $(56,403) | $(302,891) | $(439,495) | $(681,175) |
| Other comprehensive income (loss): | ||||
| Foreign currency translation adjustment | 494 | (1,599) | (2,713) | (267) |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | 1,492 | — | 1,492 | — |
| Total other comprehensive income (loss) | 1,986 | (1,599) | (1,221) | (267) |
| Comprehensive loss | $(54,417) | $(304,490) | $(440,716) | $(681,442) |
(1)Includes related party revenue of $46,659 and $8,727 for the three months ended September 30, 2024 and 2023, respectively, and $51,990 and $19,912 for the nine months ended September 30, 2024 and 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.